ABSTRACT: Trabecular bone and cortical bone have different bone remodeling levels, and the underlying mechanisms are not fully understood. In the present study, the expression of Wnt/b-catenin signaling and its downstream molecules along with bone mass in trabecular and cortical bone were compared in wild-type mice, constitutive activation of b-catenin (CA-b-catenin) mice and b-catenin deletion mice. It was found that the expression level of most of the examined genes such as Wnt3a, b-catenin, osteocalcin and RANKL/ OPG ratio were significantly higher in trabecular bone than in cortical bone in wild-type mice. CA-b-catenin resulted in up-regulated expression of the above-mentioned genes except for RANKL/OPG ratio, which were down-regulated. Also, CA-b-catenin led to increased number of osteoblasts, decreased number of osteoclasts and increased bone mass in both the trabecular bone and cortical bone compared with wild-type mice; however, the extent of changes was much greater in the trabecular bone than in the cortical bone. By contrast, null b-catenin led to down-regulated expression of the above-mentioned genes except for RANKL/OPG ratio. Furthermore, b-catenin deletion led to decreased number of osteoblasts, increased number of osteoclasts and decreased bone mass when compared with wild-type mice. Again, the extent of these changes was more significant in trabecular bone than cortical bone. Taken together, we found that the expression level of Wnt/b-catenin signaling and bone remodeling-related molecules were different in cortical bone and trabecular bone, and the trabecular bone was more readily affected by changes in the Wnt/b-catenin signaling pathway. ß
The vertebrate skeleton comprises trabecular bone (also called spongy, or cancellous bone) and cortical bone (also called compact bone). Generally speaking, trabecular bone is the type of bone mainly found in the core of short and flat bones, as well as in the metaphyses of long bones, whereas compact bone constitutes the diaphyses of the long bones and the cortical shell of short and flat bones. The two types of bone differ not only in their structure but also in their mechanical properties and metabolic activity. Structurally, cortical tissues are solid and dense and consist of osteons and plexiform lamellae aligned in the longitudinal direction of the bone. By contrast, trabecular tissues are relatively loose and contain trabecular bone packets with boundary layers at various angles compared with the longitudinal axis of the trabeculae ( Supplementary Fig. S1 ). In additional, trabecular bone has a larger surface area and trabeculae are in closer contact with vascular spaces. 1, 2 The different structures of the two types of bone tissue lead to differences in their mechanical properties. Cortical bone tissue has a higher Young's modulus compared with trabecular bone tissue, and the higher degree of mineralization of cortical bone contributes to a stiffer, but more brittle tissue compared with single trabeculae. 1, 3 In addition, cortical bone and trabecular bone show different metabolic behaviors in many physiological and pathological processes, such as glycation, pharmacokinetics, and their response to diet and implant insertion. [4] [5] [6] [7] [8] The difference in metabolic activity is best demonstrated by their different remodeling process, which has significant clinical relevance for the treatment of osteoporosis. 2, 3, [9] [10] [11] [12] Trabeculae, as thin plates, have a low matrix volume and a large surface area; therefore, signals within the matrix can readily traverse the matrix volume to locate a surface to initiate trabecular remodeling. By contrast, cortical bone has a large matrix volume and a small surface area; therefore, signals deep within the matrix may not locate a surface as readily to initiate remodeling, allowing for the accumulation of microdamage, particularly in interstitial bone that is less remodeled. 2, 10 Furthermore, different mechanoresponsiveness levels in cortical and trabecular bone lead to different bone formation abilities in response to the mechanical load on the bone. 3, 11 The different bone remodeling processes between cortical and trabecular bone may be the reason for the relative lack of efficacy of antiosteoporotic drugs on nonvertebral fractures. 9, [13] [14] [15] [16] The underlying mechanisms responsible for the different properties between cortical and trabecular bone are not fully understood. It was generally believed that the function of an organ or tissue depends on its cellular function, which is regulated by various hormones and locally acting growth factors thorough different signaling pathways. Specifically for bone, all factors influencing the composition, structure, and metabolic differences between cortical and trabecular bone do so through the final common cellular and signaling pathways, such as bone morphogenetic protein and Wnt mediated signaling pathway. 2 Accumulating evidence showed that Wnt/b-catenin signaling pathway plays a central role in bone development, bone growth and bone remodeling.
11,17-25 Thus we hypothesized that the expression levels of molecules in the Wnt/b-catenin signaling pathway in the cortical and trabecular compartments are different and that the different expression levels lead to different bone remodeling levels between cortical and trabecular bone. In the present study, the transcriptional and protein expression levels of Wnt/b-catenin signaling-related molecules were examined in the metaphyseal trabecular and diaphyseal cortical bone of the tibia in mice. Then, the biological functions of osteoblasts and osteoclasts along with bone remodeling processes were compared between the metaphyseal trabecular and diaphyseal cortical bone after b-catenin was either stabilized or deleted in mice. Tamoxifen (TM; Sigma-Aldrich, St. Louis, MO) was injected to activate the function of the promoter. Briefly, TM was dissolved in a small volume of ethanol and diluted with corn oil at a concentration of 10 mg/ml. The mice were intraperitoneally injected with TM (75 mg/kg) twice a week for 1 month, starting from postnatal day 3. 22, 25 Wild-type mice were used as controls.
METHODS

Animals
Tissue Preparation
Four weeks after birth, the mice were sacrificed with an overdose of anesthetic. The tibiae were then removed. Some samples were used for the extraction of total RNA and whole protein, and the remaining samples were fixed overnight. The fixed samples were then decalcified in 10% ethylene diaminetetra acetic acid. After the samples were adequately decalcified, they were tissue-processed, embedded in paraffin, and sectioned at a thickness of 4 mm coronally. The sections were de-paraffinized and rehydrated and then used for tartrate resistant acid phosphatase (TRAP) staining.
Real-Time Polymerase Chain Reaction Examination
After fresh tibia was taken from the mice, all soft tissues were removed, and the growth plate along with arthritic cartilage were cut off. Then the metaphyses and diaphyses were separated by cutting between their boundary, which was judged by the transition from red to white in color. The cortical shells of the metaphyses were removed. Then, 1 g of the prepared metaphyseal trabecular bone and diaphyseal bone were used to extract RNA. RNA was isolated with the TRIzol reagent (ambion, by Life Technologies, Carlsbad CA 92008) according to the manufacturer's instructions. Then, real-time PCR with the SYBR green detection method was used to examine the expression levels of Wnt3a, Wnt 4, Wnt 5a, Wnt 7, Wnt 10a, Wnt 16, LDL receptor related protein 5 (LRP 5), LRP 6, LRP 4, b-catenin,T cell factor (TCF), lymphoid enhancer-binding factor 1(LEF-1), WNT1 inducible signaling pathway protein 1 (WISP-1), axin-2, cyclin D1, c-Myc, alkaline phosphatase (ALP), osteocalcin (OCN), nuclear factor-kappaB ligand (RANKL), and osteoprotegerin (OPG). b-actin served as a control, and the expression levels of a given gene were expressed as the proportion relative to the mean b-actin value. The relative expression ratio of RANKL to OPG was calculated and used for the statistical analysis. The primers used are presented in Table 1 .
Western Bolting
For protein analysis, samples were prepared with the same method mentioned above. Then the tissue was homogenized in lysis buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 0.1 mM EDTA, 0.5% Triton-X 100, NaN3, 0.2 mM PMSF, and protease inhibitor cocktail 1:75, v/v), incubated for 30 min on ice and centrifuged 20 min at 16,000g to extract the whole protein. The whole protein extracts were then separated discontinuously on sodium dodecyl sulphate-polyacrylamide gels and transferred to polyvinylendiflouride membranes. After blocking, membranes were incubated for overnight 4˚C with the following antibodies: LRP6 (1:100, sc-17984), b-catenin (1:100, sc-7963), ALP (1:200, sc-271431), Runtrelated transcription factor 2 (Runx2, 1:100, sc-12488), cyclin D1 (1:400, sc-8396), OCN(1:50, sc-30044), and b-actin (1:1000, sc-47778). The antibodies were purchased from Santa Cruz Biotechnology, Inc., CA. These were followed by corresponding horseradish peroxidase-conjugated secondary antibodies for 1 h (1:5000, GE Healthcare Amersham, Freiburg, Germany). Protein expression was visualized using luminol-enhanced chemiluminescence and were densitometrically assessed. b-actin served as a control, and the expression levels of a given protein were expressed as the proportion relative to the mean b-actin value.
TRAP Staining
Two Coplin jars (A and B) were pre-heated to 37˚C with 50 ml stock basic incubation medium (sodium acetate anhydrous, 9.2 g, sodium tartrate dibasic dehydrate, 11.4 g, and glacial acetic acid, 2.8 ml, dissolved in 1,000 ml distilled water and the pH adjusted to 4.7-5.0 with 5 M sodium hydroxide). Then, 50 ml of 2% naphthol AS-BI phosphate substrate in ethylene glycol monoethyl ether was added to jar A, into which the slides were added and incubated at 37˚C for 45 min. A few minutes prior to the completion of the 45 min incubation, 1 ml of 5% pararosaniline chloride and 1 ml of 4% sodium nitrite was mixed for 30 s, incubated at room temperature for 2 min without mixing, and then transferred into jar B and mixed well. The slides from jar A were then moved into jar B without rinsing. Incubation at room temperature was performed for 1-3 min until the color developed, followed by rinsing and counterstaining with methyl green for 5 min, dehydration, and covering with Permount. All chemicals were purchased from the Chuandong Corporation (Chongqing, China).
DIFFERENCE BETWEEN TRABECULAR AND CORTICAL BONE
Pictures of each section were taken under a magnification of 200Â. According to the guidelines of the nomenclature committee of the American Society of Bone and Mineral Research, 26 osteoclasts were defined as boneresorbing cells covering bone surfaces and containing tartrate-resistant acid phosphatase, and osteoblasts were defined as cells covering bone surfaces after excluding osteoclasts. The number of osteoblasts and osteoclasts on bone surface in the trabecular bone (rather than the primary spongious bone) and the cortical bone (both periosteum and endosteum) was counted in five random fields and used for statistical analyses.
MicroCT Examination
The tibiae were dissected and subjected to three-dimensional microCT analysis using a viva CT 40 (Scanco Medical, Bassersdorf, Switzerland) following the procedural recommendations of the American Society for Bone and Mineral Research. 27 The scanning medium was ethanol, the X-ray tube potential was 45 kVp, and the voxel size was 10 mm.
3 Images were reconstructed and analyzed with EVS Beam software using a global threshold of 1400 Hounsfield units. Quantitative morphometric data were based on the region of interest as follows: the trabecular bone region starting from the growth plate reference level and extending 44 slices (0.8 mm) distally and cortical bone starting from the mid-diaphysis and extending 22 slices (0.4 mm) proximally. The bone volume and bone volume fraction (the percentage of bone volume to total volume, BV/TV) were calculated and used for statistical analyses.
Statistical Analysis
All data were expressed as the means AE standard deviation. In wild-type mice, the expression levels of the related molecules were compared directly between trabecular bone and cortical bone by one-way ANOVA method using the SPSS 11.0 software package.
To compare the extent of changes of the related genes and bone mass between trabecular bone and cortical bone after the stabilization of b-catenin, a comparison was firstly performed in trabecular bone or cortical bone between CA-bcatenin and wild-type mice. Then, the extent of changes of trabecular bone and cortical bone were compared by 2-way ANOVA method to observe whether there were difference between trabecular bone and cortical bone.
The same method was used to compare the extent of changes of the related molecules and bone mass between trabecular bone and cortical bone after the deletion of b-catenin.
Differences were considered significant at p < 0.05. The expression level of Wnt/b-catenin signalingrelated molecules and several molecules related to bone remodeling in metaphyseal trabecular and diaphyseal cortical bone was assessed using real-time PCR and Western Blotting. The mRNA expression levels of Wnt 3a, Wnt5a, b-catenin, TCF, LEF-1, WISP, axin-2, cyclin D1, c-Myc, and RANKL were higher in metaphyseal trabecular bone than in diaphyseal cortical bone (Fig. 1A) . The mRNA expression levels of OCN and ALP, two bone formation markers, were also higher in metaphyseal trabecular bone than in diaphyseal cortical bone (Fig. 1A) . These were further confirmed by Western Blotting examination that the protein levels of LRP6, b-catenin, ALP, Runx2, cyclin D1 and OCN in trabecular bone were higher than those in cortical bone ( Fig. 1B and C) . For bone resorption, the ratio of RANKL to OPG was higher in metaphyseal trabecular bone than in diaphyseal cortical bone (Fig. 1A) , and TRAP staining revealed that the number of TRAP-positive cells and osteoblasts was higher in metaphyseal trabecular bone than in diaphyseal cortical bone ( Fig. 2A-E ).
RESULTS
Different Expression Levels of
Trabecular and Cortical Bone Respond Differently to CA-b-Catenin
After b-catenin was stabilized in osteoblasts, the changing levels of the genes noted above in metaphyseal trabecular bone and diaphyseal cortical bone were determined. The mRNA expression levels of b-catenin, TCF, LEF-1, WISP, axin-2, cyclin D1, c-Myc, ALP, and OCN were significantly up-regulated in trabecular bone, and the degree of up-regulation of the same genes in cortical bones was not as significant as in trabecular bone (Fig. 3A) . The same trends of b-catenin, ALP, Runx2, and cyclin D1 protein expression level were confirmed by Western blotting examination ( Fig. 3B and C) . For bone resorption, the ratio of RANKL to OPG decreased in both trabecular bone and cortical bone in CA-b-catenin compared with wildtype mice, and the extent of decrease was more striking in trabecular bone (Fig. 3A) . Consistently, a decreased number of osteoclasts in both the trabecular bone and cortical bone were observed in CA-b-catenin mice compared with wild-type mice; however, the extent of changes was greater in the trabecular bone than in the cortical bone (Fig. 2F-J) .
Regarding the number of osteoblasts, it increased significantly in trabecular bone of CA-b-catenin mice, and only increased slightly in cortical bone of CAb-catenin mice compared with wild-type mice. The extent of change is more striking in trabecular bone than in cortical bone after stabilization of b-catenin (Fig. 2F-J) .
Bone mass was then examined by Micro-CT and it was revealed that the metaphyseal trabecular BV/TV increased approximately 2.4 times in CAb-catenin mice compared with wild-type mice. By contrast, the cortical bone mass only increased 0.2 times in CA-b-catenin mice compared with wild-type mice (Fig. 5) .
Taken together, these data indicate that metaphyses react more strikingly in CA-b-catenin mice and that the bone remodeling level increased more significantly in trabecular bone than in cortical bone.
Trabecular and Cortical Bone Respond Differently After Gene Deletion of b-Catenin
After b-catenin was knocked-out in mice, the mRNA expression levels of b-catenin, TCF, LEF-1, wisp, axin, cyclin D1, c-Myc, ALP, and OCN were significantly down-regulated in trabecular bone compared with wild-type mice, and the degree of down-regulation of the same genes in cortical bones was not as significant as in trabecular bone (Fig. 4A) . The same trends of b-catenin, ALP, Runx2, and cyclin D1 protein expression level were confirmed by Westernblotting examination (Fig. 4B and C) . For bone resorption, the ratio of RANKL to OPG increased in both trabecular bone and cortical bone in b-catenin knockout mice compared with wild-type mice, and the increment was more significant in trabecular bone (Fig. 4A) . Consistently, an increased number of osteoclasts was observed in both the trabecular bone and cortical bone in b-catenin knockout mice when compared with wild-type mice. Again, the extent of these changes was greater in trabecular bone than cortical bone (Fig. 2K-O) .
Regarding the number of osteoblasts, it decreased significantly in trabecular bone of b-catenin knockout mice, and only decreased slightly in cortical bone of b-catenin knockout mice compared with wild-type mice. The extent of change is more striking in trabecular bone than in cortical bone after deletion of b-catenin (Fig. 2) .
For the change of bone mass, microCT examination showed that metaphyseal trabecular BV/TV decreased approximately 0.47 times in b-catenin knockout mice compared with wild-type mice. By contrast, the corti- cal bone mass only decreased 0.19 times in b-catenin knockout mice compared with wild-type mice (Fig. 5) . These data indicate that the bone remodeling level increased more significantly in metaphyses than in the cortices after gene deletion of b-catenin.
DISCUSSION
Accumulating evidence suggests that Wnt/b-catenin signaling plays a central role in bone development, bone growth and bone remodeling. For example, b-catenin inactivation in mesenchymal progenitors, osteoblasts and osteocytes results in low bone mass, whereas b-catenin stabilization in mesenchymal progenitors and osteoblasts increases bone mass. [20] [21] [22] 25 In addition, inhibition of secreted Wnt antagonists, including SOST and DKK1, and intracellular negative regulators of the pathway, such as glycogen synthase kinase-3b (Gsk3b), may also promote bone formation and increase bone mass in rats or mice. 24 These studies revealed that the activation of Wnt/b-catenin signaling has promise for the treatment of low bone volume conditions, such as osteoporosis. Recently, it was found that manipulation of Wnt/bcatenin signaling pathway might have different effects on trabecular bone and cortical bone. For instance, osteoblast-specific overexpression of human WNT16, a ligand for Wnt/b-catenin signaling pathway which plays an important role in bone remodeling and postmenopausal fracture, increases both cortical and trabecular bone mass in mice; however, the extent of increment was more striking in trabecular bone. 28 In addition, transgenic mice over-expressing secreted frizzled-related proteins 4 (sFRP4), an antagonists of WNT signaling, under different promoters resulted in significant bone mass loss in trabecular bone but not so significant in cortical bone. 29, 30 On contrary, null of sFRP4 led to bone mass increment mainly in trabecular bone rather than in cortical bone. 31 The underlying mechanisms are current unknown. The present study found that the expression levels of Wnt/b-catenin signaling-related molecules were different in trabecular and cortical bone of tibia in mice, both at the transcriptional and protein levels. Additionally, the trabecular bone was more readily affected by changes in the Wnt/b-catenin signaling pathway. This is might the mechanisms that manipulation of Wnt/b-catenin signaling pathway had different effects on trabecular bone and cortical bone.
The findings of present study have significant clinical relevance, particularly for the prevention and treatment of osteoporosis. Research efforts have long focused on the pathogenesis and prevention of accelerated trabecular bone loss. However, it was recently found that cortical bone loss plays a more important role in the pathogenesis of osteoporosis, particularly in people aged over 60 years. Thus, cortical bone was suggested as the target for osteoporotic fracture prevention and treatment. 16, [32] [33] [34] [35] Unfortunately, most anti-osteoporosis drugs now used clinically have a greater effect on trabecular bone than cortical bone. Antiresorptive drugs, such as alendronate, have fewer effects on preventing cortical bone loss. Anabolic drugs are expected to have more effects on cortical bone. However, clinical observation found that recombinant human parathyroid hormone (rhPTH) increases bone formation in trabecular bone, but it is less effective on cortical bone. Neer et al. randomly assigned 1637 postmenopausal women with prior vertebral fractures to receive parathyroid hormone or placebo. Compared with placebo, the 40-microg doses of parathyroid hormone increased bone mineral density by 13 more percentage points in the lumbar spine, but decreased bone mineral density at the shaft of the radius by two more percentage points. 15 Another type of anabolic drug, agents that influence the Wnt signaling pathway, has more effect on cortical bone than other drugs, but its effect on cortical bone remains significantly lower than for trabecular bone. 36 This is likely caused by different expression levels of Wnt/b-catenin signaling between cortical and trabecular bone, and because trabecular bone is more easily affected by changes of Wnt/b-catenin signaling.
Importantly, cortical and cancellous bones should be considered two separate entities in the treatment of osteoporosis, and agents that have a greater effect on cortical bone loss are necessary for the improved treatment of osteoporosis. 27, 33, 36 Notably, in addition to Wnt/b-catenin signaling, estrogen, PTH and Notch signaling also play important roles in the different properties between trabecular and cortical bone. 9, 17, 36, 37 These signaling pathways might interact with each other, and Wnt/b-catenin signaling plays a central role. 9, 17, 37 For example, Canalis et al. 17 found that inactivation of Notch1 and À2 preferentially increased cancellous bone volume rather than cortical bone, and this effect was regulated by changes in the Wnt/b-catenin signaling pathway. In summary, we found that the expression levels of Wnt/b-catenin signaling molecules and bone remodeling-related molecules were different in cortical bone and trabecular bone and that the bone remodeling level in trabecular bone was more readily affected by changes in the Wnt/b-catenin signaling pathway. These differences should be considered in the treatment of osteoporosis and osteoporotic fracture. Furthermore, we suggested that the difference effects of drugs or other therapeutic medications on cortical bone and trabecular bone should be observed in order to improve the outcome.
